Case 2: Steroid-Refractory Chronic GVHD

May 14, 2021

The experts present and discuss the case of a patient with steroid-refractory chronic GVHD and discuss treatment options.

Genetic Testing Informs Treatment Decisions in Melanoma

May 14, 2021

Novel methods of genetic testing have led to improved detection and better clinical decisions in patients with melanoma, especially in the late-stage setting.

Special Episode: Oncology After COVID-19

May 14, 2021

In season 2, episode 4 of “Targeted Talks,” Benjamin O. Anderson, MD, FACS, discussed the lessons learned from the COVID-19 pandemic, and preparation for a post-COVID America.

PSMA-Directed Therapies and Diagnostics Expand Their Scope in Prostate Cancer

May 14, 2021

With the emergence of therapies that target PSMA, a cell surface transmembrane protein that is overexpressed in most prostate cancer cells, particularly in castration-resistant disease, the ability to detect and treat the disease has been transformed.

Ibrutinib Plus Venetoclax Is a Potential Second-line Regimen in MCL

May 14, 2021

Constantine S. Tam, MD, discusses how ibrutinib plus venetoclax regimen from the SYMPATICO 2938 trial may fit in the relapsed/refractory mantle cell lymphoma setting.

Pembrolizumab Achieves Prespecified Event-Free Survival in High-Risk TNBC

May 13, 2021

Patients with high-risk, early-stage triple-negative breast cancer in the phase 3 KEYNOTE-522 trial of pembrolizumab plus chemotherapy after surgery demonstrated statistically significant event-free survival.

Roundtable Discussion: Trials Demonstrate Efficacy With Different Regimens in Nonmetastatic CRPC

May 13, 2021

Eleni Efstathiou, MD, PhD, discussed clinical trials which support the use of certain treatment regimen for patients with nonmetastatic castration-resistant prostate cancer.

The Role of In-Office Next Generation Sequencing to Advance Precision Medicine in Community Oncology

May 13, 2021

The goal of precision medicine is to advance medical and scientific discoveries to offer more tailored, precise, and accurate health interventions to maximize the health benefits for patients.

Safety and Tolerability of Neoadjuvant Sunitinib in HCC

May 13, 2021

Thomas Marron, PhD, MD, discusses the safety and tolerability of neoadjuvant sunitinib in hepatocellular carcinoma.

Lenvatinib Shows Survival Benefit in Radioactive Iodine-Refractory DTC With Lung Lesions

May 13, 2021

Overall survival was prolonged in patients with radioactive iodine-refractory differentiated thyroid cancer and lung metastases larger than 1 cm who were treated with lenvatinib in the SELECT study.

Systems Approach to Oncology Needed to Implement Lessons Learned from COVID-19

May 13, 2021

In an interview with Targeted Oncology following a webinar, Benjamin O. Anderson, MD, FACS, discussed lessons from COVID-19 in further detail.

Emerging BTK-based Combination Approaches for CLL: Ibrutinib Plus Venetoclax

May 13, 2021

Findings suggest that combination regimens may extend overall and progression-free survival.